HyperMabs Inc.: federal grants and contributions: 1 agreements; $2.3M value; 1 departments; 1 programs.
Assay record ASY-CA-0OZ8NT515U · Cite as: Assay Systems, “HyperMabs Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/hypermabs-inc/
FB100 is a novel treatment for COVID-19 survivors with lung fibrosis. This project will focus on providing preclinical proof-of concept results showing antifibrotic efficacy and tolerability in relevant animal models. In addition, the project will allow HyperMabs to initiate critical manufacturing work that will support the preclinical studies a well as product characterization and release. This project represents important steps of the full non-clinical FB100 development program which will lead to clinical trials in early 2022.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.